Novavax has a milder side effect profile than mRNA COVID-19 vaccines for most people, with lower rates of injection site pain and fatigue. But both vaccine types carry similarly low risks of rare serious adverse events, including heart inflammation. The difference comes down less to one being categorically “safer” and more to how each vaccine works in your body and which tradeoffs matter to you.
How the Two Vaccines Work Differently
mRNA vaccines (Pfizer and Moderna) deliver genetic instructions that tell your cells to build copies of the spike protein found on the COVID-19 virus. Your cells manufacture those proteins, display them on their surfaces, and your immune system learns to recognize and attack them. The mRNA itself breaks down within days.
Novavax skips that step entirely. It’s a protein subunit vaccine, meaning the spike proteins are grown in a lab and delivered to you pre-made. Your immune system encounters them directly, along with an adjuvant (a booster ingredient that strengthens the immune response). This is the same basic approach used in hepatitis B and whooping cough vaccines for decades, which is one reason some people feel more comfortable with it.
Everyday Side Effects Are Milder With Novavax
Head-to-head comparisons show a clear gap in how the two platforms feel after injection. In a study published in the Journal of Infection comparing fourth doses, 70% of Moderna recipients reported injection site pain versus 35.8% of Novavax recipients. Fatigue hit 57% of the Moderna group compared to about 40% of the Novavax group. Fever was uncommon with both, at roughly 2.3% each.
CDC surveillance data shows a similar pattern across all COVID-19 vaccines: most recipients experience mild, short-lived reactions, but at least 10% reported being unable to complete daily activities during the week after vaccination in the 2023-2024 season. Symptoms were generally less frequent and less severe with additional doses compared to the initial series, and older adults had fewer reactions than younger people regardless of vaccine type.
Rare Serious Risks Are Similar
The risk that concerns most people searching this question is myocarditis, or inflammation of the heart muscle. mRNA vaccines, particularly Moderna, carry a small but documented risk of myocarditis and pericarditis (inflammation of the surrounding membrane). This risk is highest in males aged 12 to 39 and drops significantly in older adults.
Novavax was initially hoped to avoid this risk entirely. Its Phase 3 trial in adolescents reported zero cases of myocarditis, pericarditis, anaphylaxis, or Guillain-Barré syndrome. But post-marketing surveillance told a more complete story. The European Medicines Agency has documented a very small number of myocarditis and pericarditis cases following Novavax vaccination. A benefit-risk analysis estimated roughly 5.3 excess cases of myocarditis or pericarditis per 100,000 people vaccinated with Novavax, weighed against about 1,805 COVID-19 cases prevented per 100,000. So the risk exists with Novavax too, just at rates that appear lower than those seen with mRNA vaccines in younger men.
The European Medicines Agency also flagged rare reports of unusual skin sensations (tingling or reduced sensitivity to touch) and severe allergic reactions with Novavax. These remain very uncommon.
For mRNA vaccines specifically, CDC safety monitoring detected statistical signals for ischemic stroke in older adults and Guillain-Barré syndrome following the 2023-2024 Pfizer formulation. Investigators noted it remains unclear whether these signals represent true increased risks, and no similar signals had appeared with earlier mRNA formulations. Monitoring continues.
Allergy Considerations Differ by Ingredient
If you’ve had allergic reactions to vaccines or injectable medications before, the specific ingredient that may trigger a response differs between the two platforms. mRNA vaccines contain polyethylene glycol (PEG), a compound also found in laxatives, colonoscopy prep solutions, and some injectable steroids. Novavax contains polysorbate 80, which appears in several other vaccines and medications.
The two compounds are chemically related, and some people are sensitive to both. In allergy testing of patients who reacted to COVID-19 vaccines, skin prick tests identified more positive reactions to PEG, while deeper intradermal testing picked up more reactions to polysorbate 80. One patient reacted to both. True allergies to either ingredient are rare, but if you’ve had a confirmed reaction to PEG-containing products, Novavax offers an alternative, and vice versa.
Who Benefits Most From Choosing Novavax
People who experienced significant side effects from mRNA doses (days of fatigue, body aches, or fever) are the most likely to notice a practical difference by switching to Novavax. The lower reactogenicity rates mean you’re roughly half as likely to deal with injection site pain and about a third less likely to experience fatigue.
People with a known or suspected allergy to PEG have a concrete medical reason to choose Novavax instead. And some people simply prefer a vaccine technology with a longer track record, since protein subunit vaccines have been used in other contexts for over 30 years.
For the rare serious risks that drive most of the safety anxiety, the two platforms are more alike than different. Both carry a very small risk of heart inflammation. Both have demonstrated, through more than three years of global surveillance covering billions of doses, that serious adverse events are rare. The practical gap between them is real but narrow: Novavax is gentler on the body in the days after vaccination, while the long-term serious risk profile is comparable.